The Complaint alleges that defendants made false and misleading statements about Dura's supposedly well-trained and highly effective sales force, strong sales of Dura's Ceclor CD, Keftab, Nasarel/Nasalide, Rondec and Dura-Vent products, and the successful development of its new Spiros drug delivery system while forecasting its commercial release in late 1998/early 1999 and $150 million in sales by 2000, strong growth in Ceclor CD sales in 1998 to $50-55 million, 1998 earnings per share ("EPS") of $1.
24, 1998, Dura revealed that, due to weak sales of Ceclor CD, Keftab, Nasarel/Nasalide, Rondec and Dura-Vent, its 1stQ 1998 and 1998 results would be much worse than earlier forecast.
Dura commenced sales of Ceclor(SYMBOL 226 \f "Symbol")CD and Keftab
in the fourth quarter of 1996 and the response for these products has been excellent.
Dura began launching the patented antibiotic Ceclor(R) CD in November and commenced promoting sales of Keftab
Dura will begin promoting Keftab
to physicians immediately after the transaction closes and will launch and promote Ceclor CD, which was cleared for marketing by the U.
Axid (nizatidine, Lilly) Ceclor (cefaclor, Lilly) Gemzar (gemcitabine hydrochloride, Lilly) Humalog (insulin lispro, Lilly) Humulin (human insulin of recombinant DNA origin, Lilly) Humatrope (somatropin of recombinant DNA origin, Lilly) Keftab
(cephalexin hydrochloride, Dista) Keflex (cephalexin, Dista) Lorabid (loracarbef, Lilly) Prozac (fluoxetine hydrochloride, Dista) ReoPro (abciximab), Lilly Vancocin (vancomycin hydrochloride, Lilly)
Bock has marketed Lilly's Keftab
(R), another antibiotic, since 1993, and as part of this current agreement, the term of the Keftab
alliance is being extended.